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Background 
People commonly think of gout as a ‘rich man’s disease’ caused by dietary excess 
and overconsumption of alcohol, evoking stereotypical images of historical figures 
such as King Henry VIII 1. This negative perception of the condition with an historical 
link to a life of dissipation leads to underestimating the impact of gout2. 
Characterised by recurrent sudden flares of excruciating joint pain, swelling and 
inflammation, poorly treated gout can cause disabling joint damage and is 
associated with multiple comorbidities (renal impairment, metabolic syndrome, heart 
disease and depression)3. 
The prevalence of gout has increased dramatically in the UK and now affects 2.5% 
of the UK adult population; making it the most prevalent form of inflammatory 
arthritis4,5. It is four times more common in men than women and is more common in 
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older age groups, reaching its peak prevalence between the ages of 80-84 where it 
affects 15% of men and 6% of women3.  
The majority of patients with gout are managed in primary care within general 
practice. Gout is considered to be the only curable form of arthritis3 yet GP-led 
treatment for gout is sub-optimal and not concordant with current national and 
international recommendations3. In view of this, a new approach is required to 
improve the management of gout and therefore we ask ‘is there a role for the GPN?’. 
 
So what is gout? 
Essentially gout is a form of arthritis caused by the formation of monosodium urate 
crystals in and around joints. Gout results from sustained elevated serum urate 
(often reported as serum uric acid (sUA)) levels (hyperuricaemia) beyond a 
saturation point which can lead to formation and deposition of urate crystals.  
Myths and misconceptions that hyperuricaemia and gout is simply caused by 
excessive amounts of alcohol and over-eating do not tell the whole true story. Whilst 
risk factors for gout include obesity; excess consumption of beer or spirits, red meat, 
seafood, fructose-sweetened beverages, and fruit juices; in many patients gout is 
due to genetic factors; comorbid medical conditions such as hypertension, chronic 
kidney disease and obstructive sleep apnoea; or some medications (particularly 
diuretics) rather than life-style factors6. 
Hyperuricaemia is caused by over-production or renal under-excretion of urate5. 
Over 90% of people with gout have hyperuricaemia because of renal under-excretion 
of urate. Over a period of time, monosodium urate crystals form in and around the 
joints and can eventually trigger an acute gout flare. Such flares usually present with 
an excruciatingly painful, red, hot and swollen joint(s). The skin often appears shiny7. 
Acute flares come on rapidly (typically overnight) with symptoms peaking within 12-
24 hours and usually subsiding within one to two weeks5. Gout most commonly 
affects the first metatarsophalangeal (MTP) joint but can also present in other joints 
within the foot as well as the knees, ankles, elbows and hands8. It usually affects a 
single joint at a time, but several joints can be affected at once (polyarticular gout). 
Monosodium urate crystals can also form outside of the joint and under the skin 
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forming discrete firm lumps called tophi8. Gout can also cause chronic joint pain and 
erosive destructive arthritis. 
Diagnosing gout: Diagnosis is most commonly based on symptoms, clinical history 
and an examination of the affected joint. An acute flare in one joint with excruciating 
pain that peaks within 24hrs is highly characteristics of gout, particularly when the 
first MTP joint is affected3.  When diagnostic uncertainty exists, joint aspiration and 
microscopy of synovial fluid can give a definitive diagnosis. Although the serum urate 
level is elevated in people with gout, it should be noted that serum urate on its own is 
not a useful diagnostic test as most people with hyperuricaemia do not have gout 
and serum urate can be falsely low when measured during an acute flare3.  
 
Managing gout: Due to the extreme pain associated with acute flares, all patients 
should be offered or advised to use analgesia that is commenced as early as 
possible. Treatment options include non-steroidal anti-inflammatory drugs (NSAIDs) 
(such as naproxen) with a proton-pump inhibitor, low-dose colchicine, or oral 
corticosteroids, according to patient preference, past experiences and comorbidities. 
Non-pharmacological treatment such as ice-packs placed over the affected joint can 
be useful adjunctive therapy9.  
The British National Formulary recommends that Colchicine should be used in doses 
of 0.5mg two to four times daily. Diarrhoea is a common side-effect particularly at 
higher doses3. Careful consideration should be given to drug interactions with 
Colchicine. Statins should be stopped whilst taking colchicine and there should be an 
awareness of interactions with ciclosporin, ketoconazole, ritonavir, clarithromycin, 
erythromycin, verapamil and diltiazem10. Oral prednisolone at a dose of 30-35mg for 
five days has been shown to be as effective as NSAIDs7. 
Gout is often viewed as an acute episodic condition which results in a focus on the 
short-term treatment of acute flares and detracts from ”curative” long-term 
management of the condition and therefore, the most serious complications are not 
prevented2. Monosodium urate crystals can be eliminated through a combination of 
effective patient education and evidence-based ‘treat-to-target’ urate-lowering 
therapy (ULT) such as allopurinol3. 
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Long-term use of ULT is strongly recommended when patients have recurrent flares, 
tophi or chronic arthritis11. However, recently updated British and European 
guidelines state that the benefits of ULT should be explained and offered to all 
patients at diagnosis11. Optimal ULT involves a treat-to-target approach to reduce 
serum urate below the physiological saturation threshold, thereby preventing further 
crystal formation and dissolving existing crystals to prevent further flares3. European 
and American guidelines recommend lowering serum urate below 360μmol/L11,12 
whereas BSR advocates a more stringent target below 300µmo/L which leads to 
more rapid clinical improvement3,13. 
Allopurinol should be commenced at an initial dose of 100mg per day (50mg per day 
in the presence of stage-4 CKD) with a gradual monthly increase in dose (50/100mg 
increments) until the therapeutic target is achieved. The maximum daily dose of 
allopurinol is 900mg although the maximum daily dose is lower in patients with 
chronic kidney disease5. 
Despite clear guidance and recommendations, only 30-40% of people with gout take 
ULT and only 40% of those that do have the dose escalated to achieve the 
360μmol/L target14,15. Such suboptimal treatment causes frequent flares, chronic 
pain and disability, long-term joint damage, and impaired quality of life3. 
Continual monitoring and follow-up: Once ULT has been commenced patients 
should be followed-up and monitored every 4-6 weeks with regular serum urate 
measurements until the target serum urate level has been achieved. Once the serum 
urate target is reached, levels should re-checked annually as part of on-going 
assessment. Patients may still experience acute flares during the first two years after 
the target serum urate level is reached whilst existing crystal deposits dissolve, but 
these flares should eventually cease3. The critical serum urate level (the saturation 
point) is 360 µmo/L although this will show as ‘in range’ and within normal limits on 
practice computer screens, so it is crucial to know whether or not serum urate is 
above or below this critical level8. 
Is there a role for the GPN? 
It is clear that although there are multiple single disease guidelines for patients with 
multiple morbidities, the core interventions for many of the long-term condition (LTC) 
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guidelines have considerable overlap. Gout is no exception and the BSR targets 
three key areas in their 2017 guideline update: 
 Management of acute attacks 
 Modification of lifestyle and risk factors 
 Optimal use of urate-lowering therapy 
A revision of their earlier guideline was required because of the availability of the 
new pharmacological treatments, increases in incidence and prevalence, sub-
optimal management in both primary and secondary care, and a better 
understanding of barriers to effective care16,17. 
The role of the GPN has evolved such that they are now considered fundamental to 
the care of patients with LTCs18 and policy dictates that future expansion should 
bring new aspects of complex care within the GPN role, including assessment and 
diagnosis19. Over recent years, the role of GPNs has already extended within 
primary care. In 2014, NHS England published its ‘Five Year Forward View’ in which 
the need for a more flexible workforce to ‘future proof’ the NHS was made explicit20. 
GPNs have extended their working boundaries to take on roles previously 
considered outside their remit and are increasingly representing the first point of 
contact within primary care21. Specifically-trained nurses can provide care that is at 
least equivalent to that provided by GPs for ‘treat-to-target’ LTCs such as diabetes22.  
How GPNs might best become involved in the management of gout is not certain, 
but there are sufficient parallels with the treat-to-target approach in conditions such 
as diabetes to suggest that similar approaches could work. Gout information should 
be tailored to the individual patient, targeting its management (i.e modification of 
lifestyle and risk factors), and initiation and upward dose titration of ULT as per BSR 
recommendations. GPNs already have these skills but not the knowledge to utilise 
them for gout. However, a nurse-led approach to the management of gout has been 
tested23 and a recently-completed UK community-based randomised controlled trial24 
demonstrated that nurse-led care of people with gout can be superior to standard GP 
care and such a model of care is likely to be cost-effective. Table 1 provides a case 
study of a patient whose gout may be identified opportunistically. 
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Table 1. Case Study, Fred 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The GPN in this case study is ideally placed to address the lifestyle issues raised 
within this hypertension consultation such as weight management, alcohol intake 
and the fact that ideally the BP would benefit from being reduced slightly.  However, 
the GPN has the further opportunity to enquire and encourage the patient to discuss 
his medication regime, noting Fred to be taking Allopurinol, this is an indicator and 
opportunity to discuss gout and to find out how he is managing.   
Fred discloses that he has had two flares since his last annual LTC review.  He 
describes a classical presentation of pain, inflammation and swelling in his right 
great toe.  He self-managed both episodes with non-steroidal anti-inflammatories.   
CVD risk assessment found that Fred was at moderate risk of a cardiovascular event 
and this lifestyle intervention was crucial to support Fred’s understanding of the 
potential complications of gout if untreated. It had been around 2-3 months since his 
last flare and Fred’s serum urate level was measured and found to be 512μmol/L, his 
renal function was within normal range 
 
 
Fred is a 64 year old gentleman who has presented for an annual hypertension 
review with the GPN. 
   
On examination: 
BP 138/82 
Pulse 78 regular 
BMI 31 
Alcohol 16 units a week 
CVD risk assessment 17.3% 
 
Last serum uric acid level 512 µmol/L 
 
Medication: Lercanidipine 20mg, Allopurinol 100mg 
 
Investigations:  U+Es, LFTs, Lipids, HBA1c, fasting glucose, serum UA 
 
Identifying the gout medication the GPN asks about flares. 
Fred reports having two acute attacks of gout in the last 6 months that were 
excruciating and debilitating. He feels anxious about the risk of further attacks 
and describes feeling ‘down and depressed’. 
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Follow up 
 
Following discussions with Fred, it was agreed to increase the Allopurinol dose to 
200mg daily with a repeat serum urate level at 4 weeks. Further titration of 
Allopurinol up to a maximum of 900mg daily (as renal function is normal) would 
continue 4-6 weekly until the serum urate levels were below 300 µmol/L. 
NSAIDs or Colchicine cover would be provided for potential acute flares during the 
titration period.  This could be managed and supported by the GPN and is protocol 
driven. 
The GPN role is fundamental to the management of gout for patients such as Fred, 
their expertise in lifestyle advice and intervention with regard to LTC management is 
an accepted element of the role and knowledge and experience is transferable to the 
management of gout.  Fred gained an understanding of the lifestyle implications of 
weight, alcohol and CVD risk which supported him to look at behaviour change and 
modification. GPNs are ideally placed and experienced to facilitate this lifestyle 
modification and where necessary to discuss the potential use of statins in line with 
the NICE guidance for primary prevention of cardiovascular disease25.  Further risk 
assessment should be undertaken following these changes and if risk remains above 
10% a statin should be offered to support the patient 
Within 12 weeks and using 400mg Allopurinol, Fred’s serum urate level had reduced 
to 298 µmol/L, BP was 136/78, and BMI 30.2. He had had no further flares in this 3-
month period and had a good understanding of the importance of managing this 
condition with lifestyle modifications and adherence to ULT.  
 
Conclusion 
Alongside the recent publication of new guidelines for the management of gout11, two 
recent studies have demonstrated the effectiveness of suitably trained nurses to 
manage the condition23,24. For this to be so, a package of care should include 
individual patient education and patient involvement in management decisions to 
improve lifestyle and treat-to-target ULT adherence. GPNs are in a unique position to 
make a difference for patients with gout and should be encouraged to ‘take the first 
step’ to better understand gout and its management by raising the subject with their 
GPs and practice managers. 
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